May 1st, 2021
View Archives Issues
In this randomized, noninferiority trial among patients seeking emergency contraception after at least one episode of unprotected intercourse within five days of presentation, the levonorgestrel 52-mg intrauterine device (IUD) was noninferior to the copper T30A IUD at preventing pregnancy one month after IUD insertion. Adverse events between the two groups were similar.
In this prospective cohort study of 461 women, there was no association between intrauterine device use and time to conception (hazard ratio, 1.25; 95% confidence interval, 0.99-1.58). However, past Mycoplasma genitalium infection was found to be associated with longer times to conception and lower conception rates by 12 months (68% vs. 80%, P = 0.02).
This study evaluated the cost-effectiveness of extending the upper age limit of human papillomavirus (HPV) vaccination to age 30 to 45 years using two independent HPV microsimulation models and found that vaccinating in this age group was not cost-effective.
Human immunodeficiency virus (HIV) infection during pregnancy carries a significant burden to healthcare systems, and continues to be of significant public health concern.